Do clinical trial data suggest a role for SGLT2-inhibitors in primary prevention of heart failure and chronic kidney disease?
作者信息
Staessen Jan A, Janssens Stefan, Van de Werf Frans
机构信息
Research Institute Alliance for the Promotion of Preventive Medicine, Belgium.
Biomedical Science Group, Faculty of Medicine, University of Leuven, Leuven, Belgium.
出版信息
Int J Cardiol Cardiovasc Risk Prev. 2021 Sep 25;10:200100. doi: 10.1016/j.ijcrp.2021.200100. eCollection 2021 Sep.
Abstract
摘要
相似文献
1
Do clinical trial data suggest a role for SGLT2-inhibitors in primary prevention of heart failure and chronic kidney disease?临床试验数据是否表明钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂在心力衰竭和慢性肾脏病的一级预防中发挥作用？
Int J Cardiol Cardiovasc Risk Prev. 2021 Sep 25;10:200100. doi: 10.1016/j.ijcrp.2021.200100. eCollection 2021 Sep.
2
Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus.钠-葡萄糖协同转运蛋白 2 抑制剂对糖尿病患者左心室舒张功能的潜在影响。
Heart Fail Rev. 2018 May;23(3):439-444. doi: 10.1007/s10741-018-9668-1.
3
Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.达格列净对伴有慢性心力衰竭的 2 型糖尿病患者左心室舒张功能的影响。
Cardiovasc Diabetol. 2018 Oct 8;17(1):132. doi: 10.1186/s12933-018-0775-z.
4
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.恩格列净对射血分数降低的慢性心力衰竭患者发病率和死亡率影响的评估：EMPEROR-Reduced 试验的原理和设计。
Eur J Heart Fail. 2019 Oct;21(10):1270-1278. doi: 10.1002/ejhf.1536. Epub 2019 Jul 16.
5
Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.钠-葡萄糖协同转运蛋白 2 抑制剂在糖尿病患者中心肾保护作用：从心力衰竭和糖尿病肾病的生物标志物到临床结局。
Metabolism. 2022 Jan;126:154918. doi: 10.1016/j.metabol.2021.154918. Epub 2021 Oct 23.
6
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.SGLT2 抑制剂在 2 型糖尿病患者的慢性肾脏病和心血管疾病中的应用：美国国家肾脏基金会科学研讨会报告。
Am J Kidney Dis. 2021 Jan;77(1):94-109. doi: 10.1053/j.ajkd.2020.08.003. Epub 2020 Oct 26.
7
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.钠-葡萄糖共转运蛋白 2 抑制剂在非糖尿病慢性肾脏病患者中的应用。
Adv Ther. 2021 May;38(5):2201-2212. doi: 10.1007/s12325-021-01735-5. Epub 2021 Apr 16.
8
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.SGLT2 抑制剂在心血管疾病和肾功能障碍中的保护作用机制。
Curr Top Med Chem. 2019;19(20):1818-1849. doi: 10.2174/1568026619666190828161409.
9
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.SGLT2 抑制剂预防 2 型糖尿病患者肾衰竭：系统评价和荟萃分析。
Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854. doi: 10.1016/S2213-8587(19)30256-6. Epub 2019 Sep 5.
10
Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.钠-葡萄糖协同转运蛋白2（SGLT2）抑制对心力衰竭合并糖尿病患者左心室重构影响的研究（REFORM）试验原理与设计
Cardiovasc Diabetol. 2016 Jul 15;15:97. doi: 10.1186/s12933-016-0419-0.
引用本文的文献
1
Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction.射血分数保留的心力衰竭患者平均压和脉压的临床意义。
Hypertension. 2022 Jan;79(1):241-250. doi: 10.1161/HYPERTENSIONAHA.121.17782. Epub 2021 Nov 5.
本文引用的文献
1
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.钠-葡萄糖协同转运蛋白 2 抑制剂在射血分数降低的心力衰竭患者中的应用：EMPEROR-Reduced 和 DAPA-HF 试验的荟萃分析。
Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.
2
Opportunities of Antidiabetic Drugs in Cardiovascular Medicine: A Meta-Analysis and Perspectives for Trial Design.抗糖尿病药物在心血管医学中的机遇：荟萃分析及试验设计视角。
Hypertension. 2020 Aug;76(2):420-431. doi: 10.1161/HYPERTENSIONAHA.120.14791. Epub 2020 Jul 8.
3
Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction.指导舒张性左心室功能障碍尿液肽组学标志物临床应用的流行病学观察
J Am Soc Hypertens. 2018 Jun;12(6):438-447.e4. doi: 10.1016/j.jash.2018.03.007. Epub 2018 Mar 21.
4
Treatment of heart failure with normal ejection fraction: an inconvenient truth!射血分数正常心力衰竭的治疗：一个尴尬的真相！
J Am Coll Cardiol. 2010 Feb 9;55(6):526-37. doi: 10.1016/j.jacc.2009.06.067.
5
Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes.大型随机对照试验的荟萃分析，以评估他汀类药物对心血管结局的影响。
Br J Clin Pharmacol. 2004 May;57(5):640-51. doi: 10.1111/j.1365-2125.2003.02060.x.
Zotero 插件